Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1399-1414

  Alameh, Mohamad ^a   de Jesus, Diogo ^a   Jean, Myriam ^a   Darras, Vincent ^a   Thibault, Marc ^a   Lavertu, Marc ^a   Buschmann, Michael D ^a   Merzouki, Abderrazzak ^a  

^a ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

Author keywords

ApoB; Chitosan; Gene silencing; Nonviral delivery system; RecQL1; SiRNA

Indexed keywords

APOLIPOPROTEIN B; DOUBLE STRANDED OLIGODEOXYNUCLEOTIDE; LOW MOLECULAR WEIGHT CHITOSAN NANOPARTICLE; MESSENGER RNA; NANOPARTICLE; OLIGODEOXYNUCLEOTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CHITOSAN;

AMINE TO PHOSPHATE RATIO; ANALYTICAL PARAMETERS; APOB GENE; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONFOCAL MICROSCOPY; DEPOLYMERIZATION; GENE; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; IN VITRO GENE TRANSFER; IN VITRO STUDY; LIGHT SCATTERING; MOLECULAR WEIGHT; NUCLEASE PROTECTION ASSAY; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; RECQL1 GENE; RNA INTERFERENCE; RNA SEQUENCE; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CELL LINE; CELL STRAIN HEK293; CELL STRAIN HEPG2; CELL SURVIVAL; CHEMISTRY; CYTOCHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; HUMAN; METHODOLOGY; MOUSE; PLASMID;

ANIMALS; CELL LINE; CELL SURVIVAL; CHITOSAN; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; GENE SILENCING; HEK293 CELLS; HEP G2 CELLS; HISTOCYTOCHEMISTRY; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICROSCOPY, CONFOCAL; MOLECULAR WEIGHT; NANOPARTICLES; PARTICLE SIZE; PLASMIDS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84862329042     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S26571     Document Type: Article

References (86)

1. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6(6):443-453.
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-811.
3. Alameh M, Jean M, DeJesus D, Buschmann MD, Merzouki A. Chitosanase-based method for RNA isolation from cells transfected with chitosan/siRNA nanocomplexes for real-time RT-PCR in gene silencing. Int J Nanomedicine. 2010;5:473.
4. Bantounas I, Phylactou LA, Uney JB. RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol. 2004;33(3):545-557.
5. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interferencebased therapeutics. Nature. 2009;457(7228):426-433.
6. Futami K, Kumagai E, Makino H, et al. Induction of mitotic cell death in cancer cells by small interference RNA suppressing the expression of RecQL1 helicase. Cancer Sci. 2008;99(1):71-80.
7. Futami K, Kumagai E, Makino H, et al. Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models. Cancer Sci. 2008; 99(6):1227-1236.
8. Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther. 2006;14(4):476-484.
9. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173-178.
10. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089):111-114.
11. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494-498.
12. Whelan J. First clinical data on RNAi. Drug Discov Today. 2005;10(15): 1014-1015.
13. Corey DR. RNA learns from antisense. Nat Chem Biol. 2007;3(1): 8-11.
14. Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest. 2007;117(12):3615-3622.
15. Stein CA. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends Biotechnol. 1996;14(5):147-149.
16. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting throught systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2004; 12(5):461-466.
17. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115(2): 216-225.
18. Elmen J, Thonberg H, Ljungberg K, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33(1):439-447.
19. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther. 2006;13(3):494-505.
20. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2): 129-138.
21. Bramsen JB, Laursen MB, Nielsen AF, et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 2009;37(9):2867-2881.
22. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. RNA. 2004;10(5):766-771.
23. Weyermann J, Lochmann D, Georgens C, Zimmer A. Albuminprotamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect. Eur J Pharm Biopharm. 2005; 59(3):431-438.
24. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 2003; 31(2):589-595.
25. Parrish S, Fleenor J, Xu S, Mello C, Fire A. Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol Cell. 2000;6(5):1077-1087.
26. Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry. 2003; 42(26):7967-7975.
27. Harborth J, Elbashir SM, Vandenburgh K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 2003;13(2):83-105.
28. Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med (Maywood). 2001;226(9):825-830.
29. Tousignant JD, Gates AL, Ingram LA, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther. 2000; 11(18):2493-2513.
30. Ishida T, Ichihara M, Wang X, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release. 2006;112(1):15-25.
31. Judge A, McClintock K, Phelps JR, MacLachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther. 2006;13(2):328-337. Epub November 7, 2005.
32. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther. 2005;312(3):1020-1026. Epub November 3, 2004.
33. Boeckle S, von Gersdorff K, van der Piepen S, Culmsee C, Wagner E, Ogris M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J Gene Med. 2004;6(10):1102-1111.
34. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther. 2005;11(6):990-995.
35. Hunter AC, Moghimi SM. Cationic carriers of genetic material and cell death: a mitochondrial tale. Biochim Biophys Acta. 2010; 1797(6-7):1203-1209.
36. Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 2009;(4):671-681. Epub October 16, 2009.
37. Jean M, Smaoui F, Lavertu M, et al. Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies. Gene Ther. 2009;16(9): 1097-1110.
38. Lavertu M, Méthot S, Tran-Khanh N, Buschmann MD. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials. 2006;27(27):4815-4824.
39. Nimesh S, Thibault MM, Lavertu M, Buschmann MD. Enhanced gene delivery mediated by low molecular weight chitosan/DNA complexes: effect of pH and serum. Mol Biotechnol. 2010;46(2):182-196.
40. Thibault M, Nimesh S, Lavertu M, Buschmann MD. Intracellular trafficking and decondensation kinetics of chitosan-pDNA polyplexes. Mol Ther. 2010;18(10):1787-1795.
41. Jean M, Alameh M, Buschmann MD, Merzouki A. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of Type 2 Diabetes. Gene Ther. 2011;18(8):807-816.
42. Howard KA, Kjems J. Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert Opin Biol Ther. 2007;7(12):1811-1822.
43. Liu X, Howard KA, Dong M, et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials. 2007;28(6):1280-1288.
44. de Campos AM, Diebold Y, Carvalho EL, Sanchez A, Alonso MJ. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res. 2004;21(5): 803-810.
45. Onishi H, Machida Y. Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials. 1999;20(2):175-182.
46. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62(1):12-27.
47. Richardson SC, Kolbe HV, Duncan R. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm. 1999;178(2):231-243.
48. Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res. 2004;21(2):344-353.
49. Wiegand C, Winter D, Hipler UC. Molecular-weight-dependent toxic effects of chitosans on the human keratinocyte cell line HaCaT. Skin Pharmacol Physiol. 2010;23(3):164-170.
50. Ma PL, Buschmann MD, Winnik FM. One-step analysis of DNA/ chitosan complexes by field-flow fractionation reveals particle size and free chitosan content. Biomacromolecules. 2010;11(3):549-554.
51. Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005;258(5):395-410.
52. Sharma S, Doherty KM, Brosh RM Jr. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability. Biochem J. 2006;398(3):319-337.
53. Scaringe SA, Wincott FE, Caruthers MH. Novel RNA synthesis method using 5g-silyl-2--orthoester protecting groups. J Am Chem Soc. 1998;120:11820-11821.
54. Nguyen S, Hisiger S, Jolicoeur M, Winnik FM, Buschmann MD. Fractionation and characterization of chitosan by analytical SEC and 1H-NMR after semi-preparative SEC. Carbohydr Polym. 2009;75:636-646.
55. Nguyen S, Winnik FM, Buschmann MD. Improved reproducibility in the determination of the molecular weight of chitosan by analytical size exclusion chromatography. Carbohydr Polym. 2009;75:528-533.
56. Lavertu M, Xia Z, Serreqi AN, et al. A validated 1H-NMR method for the determination of the degree of deacetylation of chitosan. J Pharm Biomed Anal. 2003;32(6):1149-1158.
57. Skrypina NA, Timofeeva AV, Khaspekov GL, Savochkina LP, Beabealashvilli R. Total RNA suitable for molecular biology analysis. J Biotechnol. 2003;105(1-2):1-9.
58. Quong D, Neufeld RJ. DNA protection from extracapsular nucleases, within chitosan-or poly-L-lysine-coated alginate beads. Biotechnol Bioeng. 1998;60(1):124-134.
59. Ma PL, Lavertu M, Winnik FM, Buschmann MD. New insights into chitosan-DNA interactions using isothermal titration microcalorimetry. Biomacromolecules. 2009;10(6):1490-1499.
60. Nel AE, Madler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543-557.
61. Wu L, Hickson ID. DNA helicases required for homologous recombination and repair of damaged replication forks. Annu Rev Genet. 2006;40:279-306.
62. Kawabe T, Tsuyama N, Kitao S, et al. Differential regulation of human RecQ family helicases in cell transformation and cell cycle. Oncogene. 2000;19(41):4764-4772.
63. Schaefer JR, Scharnagl H, Baumstark MW, et al. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb Vasc Biol. 1997;17(2):348-353.
64. Itabe H. Oxidative modification of LDL: its pathological role in atherosclerosis. Clin Rev Allergy Immunol. 2009;37(1):4-11.
65. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 1995;16:215-233.
66. Bivas-Benita M, Romeijn S, Junginger HE, Borchard G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm. 2004;58(1):1-6.
67. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-347.
68. Guy J, Drabek D, Antoniou M. Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy. Mol Biotechnol. 1995;3(3):237-248.
69. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13(12):1838-1845.
70. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst. 1992; 9(2):135-187.
71. Jean M, Alameh M, De Jesus D, et al. Chitosan-based therapeutic nanocomplexes for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes. Eur J Pharm Sci. 2011; 45(1-2):138-149. Epub November 9, 2011.
72. Chithrani BD, Chan WC. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 2007;7(6):1542-1550.
73. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006;6(4):662-668.
74. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010;6(1):12-21.
75. Liu W, Sun S, Cao Z, et al. An investigation on the physicochemical properties of chitosan/DNA polyelectrolyte complexes. Biomaterials. 2005;26(15):2705-2711.
76. Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res. 1998;15(9):1332-1339.
77. Danielsen S, Strand S, de Lange Davies C, Stokke BT. Glycosaminoglycan destabilization of DNA-chitosan polyplexes for gene delivery depends on chitosan chain length and GAG properties. Biochim Biophys Acta. 2005;1721(1-3):44-54. Epub November 2, 2004.
78. Köping-Höggård M, Mel'nikova YS, Vårum KM, Lindman B, Artursson P. Relationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery system in vitro and in vivo. J Gene Med. 2003;5(2):130-141.
79. Gao S, Dagnaes-Hansen F, Nielsen EJ, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 2009;17(7):1225-1233.
80. Ji AM, Su D, Che O, et al. Functional gene silencing mediated by chitosan/ siRNA nanocomplexes. Nanotechnology. 2009;20(40):405103.
81. Bishop NE. An Update on Non-clathrin-coated Endocytosis. Rev Med Virol. 1997;7(4):199-209.
82. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res. 2002;19(10):1488-1494.
83. Center for Biologics Evaluation and Research, US Food and Drug Administration. Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications. Rockville, MD;2007. Available from: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ ucm074770.htm. Accessed January 1, 2012.
84. Center for Biologics Evaluation and Research. Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications. Rockville, MD: US FDA; 2007. Available from: http://iccvam. niehs.nih.gov/SuppDocs/FedDocs/FDA/FDA_plasdnavac.pdf. Accessed February 23, 2012.
85. Center for Biologics Evaluation and Research. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). Rockville, MD: US FDA; 2008. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/ CellularandGeneTherapy/ucm078694.pdf. Accessed February 23, 2012.
86. US Pharmacopeial Convention. Gene therapy products. In: Second Supplement to USP 34-NF 29. Rockville, MD: United States Pharmacopeial;2011:5135-5158.